These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1023 related articles for article (PubMed ID: 34746689)

  • 21. Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity.
    Gong SY; Chatterjee D; Richard J; Prévost J; Tauzin A; Gasser R; Bo Y; Vézina D; Goyette G; Gendron-Lepage G; Medjahed H; Roger M; Côté M; Finzi A
    Virology; 2021 Nov; 563():134-145. PubMed ID: 34536797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization.
    Tang H; Gao L; Wu Z; Meng F; Zhao X; Shao Y; Hou G; Du X; Qin FX
    Front Immunol; 2022; 13():836232. PubMed ID: 35371108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural Consequences of Variation in SARS-CoV-2 B.1.1.7.
    Ostrov DA
    J Cell Immunol; 2021; 3(2):103-108. PubMed ID: 33969357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.
    Ferrari M; Mekkaoui L; Ilca FT; Akbar Z; Bughda R; Lamb K; Ward K; Parekh F; Karattil R; Allen C; Wu P; Baldan V; Mattiuzzo G; Bentley EM; Takeuchi Y; Sillibourne J; Datta P; Kinna A; Pule M; Onuoha SC
    J Virol; 2021 Sep; 95(19):e0068521. PubMed ID: 34287040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in Japan.
    Furukawa K; Tjan LH; Sutandhio S; Kurahashi Y; Iwata S; Tohma Y; Sano S; Nakamura S; Nishimura M; Arii J; Kiriu T; Yamamoto M; Nagano T; Nishimura Y; Mori Y
    Open Forum Infect Dis; 2021 Oct; 8(10):ofab430. PubMed ID: 34631915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation.
    Rodriguez JA; Gonzalez J; Arboleda-Bustos CE; Mendoza N; Martinez C; Pinzon A
    Chem Biol Interact; 2022 Dec; 368():110244. PubMed ID: 36336003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
    Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
    Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.
    Neerukonda SN; Wang R; Vassell R; Baha H; Lusvarghi S; Liu S; Wang T; Weiss CD; Wang W
    J Virol; 2022 Sep; 96(17):e0114022. PubMed ID: 36000843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variations in Cell Surface ACE2 Levels Alter Direct Binding of SARS-CoV-2 Spike Protein and Viral Infectivity: Implications for Measuring Spike Protein Interactions with Animal ACE2 Orthologs.
    Kazemi S; López-Muñoz AD; Hollý J; Jin L; Yewdell JW; Dolan BP
    J Virol; 2022 Sep; 96(17):e0025622. PubMed ID: 36000847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera.
    Hu J; Wei XY; Xiang J; Peng P; Xu FL; Wu K; Luo FY; Jin AS; Fang L; Liu BZ; Wang K; Tang N; Huang AL
    Genes Dis; 2022 Sep; 9(5):1290-1300. PubMed ID: 34877393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. South African (501Y.V2) and the United Kingdom (B.1.1.7) SARS-CoV-2 Spike (S) Protein Variants Demonstrate a Higher Binding Affinity to ACE2.
    Mohammad A; Abubaker J; Al-Mulla F
    Comb Chem High Throughput Screen; 2023; 26(3):589-594. PubMed ID: 35674297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
    Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
    EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 Variants of Concern and Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity.
    Liu H; Wei P; Kappler JW; Marrack P; Zhang G
    Front Immunol; 2022; 13():825256. PubMed ID: 35154144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects.
    Nguyen HT; Zhang S; Wang Q; Anang S; Wang J; Ding H; Kappes JC; Sodroski J
    J Virol; 2021 Mar; 95(5):. PubMed ID: 33310888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways.
    Laporte M; Raeymaekers V; Van Berwaer R; Vandeput J; Marchand-Casas I; Thibaut HJ; Van Looveren D; Martens K; Hoffmann M; Maes P; Pöhlmann S; Naesens L; Stevaert A
    PLoS Pathog; 2021 Apr; 17(4):e1009500. PubMed ID: 33886690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. D614G Substitution of SARS-CoV-2 Spike Protein Increases Syncytium Formation and Virus Titer via Enhanced Furin-Mediated Spike Cleavage.
    Cheng YW; Chao TL; Li CL; Wang SH; Kao HC; Tsai YM; Wang HY; Hsieh CL; Lin YY; Chen PJ; Chang SY; Yeh SH
    mBio; 2021 Aug; 12(4):e0058721. PubMed ID: 34311586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
    Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
    J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV-2 spike protein variant binding affinity to an angiotensin-converting enzyme 2 fusion glycoproteins.
    Matthews AM; Biel TG; Ortega-Rodriguez U; Falkowski VM; Bush X; Faison T; Xie H; Agarabi C; Rao VA; Ju T
    PLoS One; 2022; 17(12):e0278294. PubMed ID: 36472974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolution, correlation, structural impact and dynamics of emerging SARS-CoV-2 variants.
    Spratt AN; Kannan SR; Woods LT; Weisman GA; Quinn TP; Lorson CL; Sönnerborg A; Byrareddy SN; Singh K
    Comput Struct Biotechnol J; 2021; 19():3799-3809. PubMed ID: 34188776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant.
    Ren W; Zhang Y; Rao J; Wang Z; Lan J; Liu K; Zhang X; Hu X; Yang C; Zhong G; Zhang R; Wang X; Shan C; Ding Q
    mBio; 2023 Apr; 14(2):e0041623. PubMed ID: 37010428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.